29.08.2016 • NewsElaine BurridgeLanxessmembranes

Lanxess to Double German Membranes Capacity

(c) Lanxess
(c) Lanxess

Lanxess has decided to double capacity for reverse osmosis (RO) membranes at its site in Bitterfeld, Germany, in order to meet rising demand. Jean-Marc Vesselle, head of Lanxess’ Liquid Purification Technologies business unit, said the Lewabrane plant, which is operated by wholly owned subsidiary IAB Ionenaustrauscher, is currently operating at close to its limit. The additional production will go on stream in the second half of 2017, creating up to 10 new jobs.

According to Lanxess, the market for RO membrane elements is forecast to grow at an above-average rate of 10% per year to 2020. The company added that it continuously researches all areas of modern water treatment, co-operating with the Fraunhofer Institutes for Factory Operation and Automation (IFF) in Magdeburg, and for Microstructure of Materials and Systems (IMWS) in Halle, for example.

Lanxess said it has spent €40 million on the Bitterfeld site in the last five years, growing during that time to become a leading player in the water treatment market. The Cologne-headquartered specialty chemical company also operates ion exchange resins plants in Leverkusen, Germany, and Jhagadia, India.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.